ArticleFrontiers in oncology2022
Head-to-Head Comparison of the Expression Differences of NECTIN-4, TROP-2, and HER2 in Urothelial Carcinoma and Its Histologic Variants.
Article in Frontiers in oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 30 citations in OpenAlex.
- Neuroendocrine Neoplasms of the Urinary Bladder: Integrating Molecular Advances into a Refined Classification System.Endocrine pathology · 2026Review
- Review
- Heterogeneity of urinary system tumors: novel avenues for targeted therapy and precision medicine.Journal of advanced research · 2026Review
- Nectin4-targeted molecular imaging for precise endoscopic diagnosis and image-guided surgery in bladder cancer.Cell reports. Medicine · 2026Article
- Features of tumor microenvironment in HER2-positive urothelial carcinoma and its implications for immunotherapy resistance.BMC cancer · 2026Article
- Immune checkpoint inhibitors in bladder cancer: from mechanistic insights to emerging combination frontlines.Clinical and experimental medicine · 2026Review
- Expression of Nectin-4 and Trop-2 in upper tract urothelial carcinoma: implications for biomarker-driven antibody-drug conjugate therapy.The journal of pathology. Clinical research · 2026Article
- The 2025 paradigm shift in urothelial carcinoma pharmacotherapy: from chemotherapy to ADCs and ICIs.Frontiers in cell and developmental biology · 2026Review
- Spatial distribution and subtype-specific expression patterns of Nectin-4 in muscle-invasive bladder cancer.BJU international · 2025Article
- Assessing the expression of Nectin-4 in solid tumors by immunohistochemistry - what do we know?Histology and histopathology · 2025Review
- Trop-2 and Ephrin B2 expression in urothelial carcinoma with divergent differentiation and aggressive urothelial carcinoma subtypes.American journal of clinical pathology · 2025Article
- Efficacy and safety of a novel treatment scheme of RC48-ADC plus PD-1 inhibitors in metastatic urothelial carcinoma: a multicenter real-world study.Therapeutic advances in medical oncology · 2025Article
- PD-L1 and nectin-4 expression and genomic characterization of bladder cancer with divergent differentiation.Cancer · 2024Article
- Initial experience of enfortumab vedotin in a patient with metastatic urothelial carcinoma on hemodialysis: Two case reports.IJU case reports · 2024Article
- Antibody-Drug Conjugates in the Treatment of Genitourinary Cancers: An Updated Review of Data.Current oncology (Toronto, Ont.) · 2024Review
- Prognostic Impact of Histologic Subtype and Divergent Differentiation in Patients with Metastatic Urothelial Carcinoma Treated with Enfortumab Vedotin: A Multicenter Retrospective Study.Current oncology (Toronto, Ont.) · 2024Article
- One Size Fits Some: Approaching Rare Malignancies of the Urinary Tract.Current treatment options in oncology · 2024Review
- Expression of HER2 in high-grade urothelial carcinoma based on Chinese expert consensus and the clinical effects of disitamab vedotin-tislelizumab combination therapy in the treatment of advanced patients.Frontiers in pharmacology · 2024Article
- Precision Medicine in Urothelial Carcinoma: Current Markers to Guide Treatment and Promising Future Directions.Current treatment options in oncology · 2023Review
- Targeted therapies in bladder cancer: signaling pathways, applications, and challenges.MedComm · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Antibody-drug conjugates (ADC), such as enfortumab vedotin (EV), sacituzumab govitecan (SG), and RC-48, have shown outstanding response rates to local advanced or metastatic urothelial carcinoma (UC). However, their corresponding target expression characteristics in UC and its histologic variants were unknown. Methods: We detected the expression of NECTIN-4, TROP-2, and HER2, which are the corresponding targets of ADCs EV, SG, and RC-48 in muscle-invasive UC through immunohistochemistry. Results: 161 consecutive samples from 2017 to 2021 of muscle-invasive UC and its histologic variants were obtained in Peking University First Hospital. Variant histology types included 72UC, 10 squamous carcinomas, 23 glandular carcinomas, 19 small cell carcinomas, 19 micropapillary variants, and 18 nested variants. NECTIN-4 expression was found to be 57/72 (79.2%), 10/10 (100%), 15/23 (65.2%), 4/19 (21.1%), 15/19 (78.9%), and 16/18 (88.9%) in conventional UC, squamous carcinoma, glandular carcinoma, small cell carcinoma, micropapillary, and nested variant, respectively, compared with 65/72 (90.3%), 8/10 (80.0%), 13/23 (56.5%), 3/19 (15.8%), 16/19 (84.2%), and 15/18 (83.3%) of TROP-2, and 26/72 (36.1%), 0, 5/23 (21.7%), 6/19 (31.6%), 5/19 (26.3%), and 7/18 (38.9%) of HER2.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.